PsychoPathology/DSM Diagnoses Study Notes

PsychoPathology/DSM Diagnoses Study Notes

I. Overview of Neurodevelopmental Disorders

  • Definition: Early-onset developmental deficits affecting:

    • Personal functioning

    • Social functioning

    • Academic functioning

    • Occupational functioning

  • Symptom Onset: Symptoms begin early in development (often before school age) and are typically lifelong.

II. Intellectual Developmental Disorder (Intellectual Disability)

A. Diagnostic Criteria (Must include ALL three)
  1. Deficits in Intellectual Functioning:

    • Confirmed by clinical assessment + standardized testing

    • IQ ≈ two standard deviations (SD) below the mean (~70 or below)

  2. Deficits in Adaptive Functioning:

    • Affects conceptual, social, and practical domains

    • Must limit personal independence and social responsibility

  3. Onset: During developmental period

Severity Specifiers
  • Severity: Based on adaptive functioning, NOT IQ:

    • Mild

    • Moderate

    • Severe

    • Profound

B. Etiology
  • Cause identified in 25–50% of cases. Of known causes:

    • 80–85% prenatal (e.g., genetic/chromosomal, teratogens, maternal illness)

    • 5–10% perinatal (e.g., birth asphyxia)

    • 5–10% postnatal (e.g., TBI, infection, toxins)

  • Genetic Causes:

    • Down Syndrome: Most common chromosomal cause (NOT inherited; caused by trisomy 21)

    • Fragile X Syndrome: Most common inherited cause (mutated gene on X chromosome)

III. Autism Spectrum Disorder (ASD)

A. Diagnostic Criteria (Requires BOTH)
  1. Deficits in Social Communication/Interaction:

    • Social-emotional reciprocity

    • Nonverbal communication

    • Understanding/maintaining relationships

  2. Restricted, Repetitive Behaviors:

    • Repetitive movements/speech

    • Insistence on sameness, routines

    • Highly fixated interests

    • Hyper- or hypo-reactivity to sensory input

  • Onset: Symptoms must begin in early development.

B. Associated Features
  • Intellectual impairment

  • Language impairment

  • Self-injury (e.g., head banging, biting)

  • Motor abnormalities (e.g., clumsiness, toe-walking)

  • Deficits in face and emotion recognition

C. Prognosis (EPPP MUST KNOW)
  • Best Outcomes Associated With:

    • IQ > 70

    • Functional language by age 5

    • Fewer comorbid psychiatric conditions

D. Epidemiology
  • Global prevalence: 1%

  • U.S. prevalence: 3.2% of 8-year-olds

  • More common in males (3–4:1)

E. Etiology
  • Combination of Genetic + Environmental Factors.

  • Heredity:

    • Twin studies:

    • Heritability ≈ 62%

    • Monozygotic (MZ): 59–84%

    • Dizygotic (DZ): 3–29%

  • Environmental Factors:

    • Very preterm birth (<26 weeks)

    • Prenatal valproic acid exposure

    • Advanced parental age

    • NO evidence linking vaccines → ASD

F. Neurobiology
  • Accelerated Brain Growth: Between 6 months and preschool

  • Abnormalities:

    • Cerebellum

    • Corpus callosum

    • Amygdala

  • Serotonin Irregularities:

    • Low brain serotonin

    • High blood serotonin

  • Also involves dopamine, GABA, glutamate, acetylcholine.

G. Treatment
  1. Nonpharmacological:

    • Early Intensive Behavioral Intervention (EIBI)

    • Applied Behavior Analysis (ABA)

    • Most impact on IQ & language development

    • Fewer consistent effects on social/adaptive functioning

  2. Medication:

    • NOT effective for core ASD symptoms

    • Used for comorbidity:

      • Stimulants → ADHD symptoms

      • SSRIs → anxiety/depression

      • Atypical antipsychotics (e.g., risperidone, aripiprazole) → irritability/aggression

IV. Attention-Deficit/Hyperactivity Disorder (ADHD)

A. Diagnostic Criteria
  • Symptoms for ≥ 6 months:

    • Onset before age 12

    • Present in 2 or more settings

    • Cause impairment:

    • Ages ≤16: 6 symptoms required

    • Ages ≥17: 5 symptoms required

Presentations
  • Predominantly inattentive

  • Predominantly hyperactive/impulsive

  • Combined

B. Common Symptoms
  1. Inattention:

    • Forgetful

    • Easily distracted

    • Careless mistakes

    • Difficulty sustaining attention

  2. Hyperactivity-Impulsivity:

    • Excessive talking

    • Fidgeting

    • Running/climbing

    • Interrupts others

C. Epidemiology
  • Most prevalent diagnosed disorder in youth (U.S.)

  • 2:1 male:female ratio in childhood

  • 1.6:1 ratio in adulthood

D. Course into Adulthood
  • Hyperactivity → restlessness

  • Impulsivity → risky decisions

  • Inattention → chronic disorganization, missed deadlines

  • Most continue to experience some symptoms as adults.

E. Neurobiology
  • Structural + functional abnormalities in:

    • Prefrontal cortex

    • Striatum

    • Thalamus

    • Cerebellum

    • Amygdala

  • Neurotransmitter involvement:

    • Low dopamine and norepinephrine contribute to symptoms.

F. Etiology
  • Twin studies: show high heritability (~74%)

  • Environmental Contributors:

    • Low birth weight

    • Time in NICU

    • Developmental delays

G. Treatment
  1. Children:

    • Preschool: behavioral parent training (PTBM, PCIT)

    • School age: medication + behavioral interventions

    • Adolescents: medication + school supports + motivational interviewing (MI), mindfulness

  2. Adults:

    • First-line: medication

    • CBT has strongest psychosocial evidence

    • Stimulant treatment does not increase or decrease later substance use risk.

V. Tic Disorders

  • Definition: Tic = sudden, rapid, recurrent, non-rhythmic movement or sound.

Types:
  • Motor Tics: (e.g., eye blink, shrug, grimace)

  • Vocal Tics: (e.g., throat clearing, barking, echolalia)

A. Disorders
  1. Tourette’s Disorder:

    • Multiple motor tics + at least one vocal tic

    • Present for >1 year

    • Onset before age 18

  2. Persistent (Chronic) Motor or Vocal Tic Disorder:

    • Motor OR vocal tics (not both)

    • Present >1 year

  3. Provisional Tic Disorder:

    • Motor and/or vocal tics

    • <1 year duration

  • Peak Severity: Ages 10–12

  • Common Comorbidity: ADHD

B. Etiology
  • Biological Factors:

    • Dopamine overactivity

    • Smaller caudate nucleus

    • Genetic factors

C. Treatment
  • Medications:

    • Antipsychotics (e.g., haloperidol)

    • Meds for comorbid ADHD or OCD

    • CBIT (Comprehensive Behavioral Intervention for Tics):

    • Habit reversal

    • Competing response

    • Relaxation training

VI. Communication Disorders

Childhood-Onset Fluency Disorder (Stuttering)
  • Key Symptoms:

    • Sound/syllable repetitions

    • Prolongations

    • Blocking

    • Circumlocutions

    • Excessive tension

    • Monosyllabic word repetitions

  • Onset: Ages 2–7

  • Recovery Rate: 65–85% recover naturally

  • Best Treatment: Habit reversal training (regulated breathing)

VII. Specific Learning Disorder (SLD)

A. Diagnostic Criteria
  • Difficulties in academic skills for ≥ 6 months despite interventions.

  • Must impair academic, occupational, or daily functioning.

B. Subtypes
  • Reading (dyslexia)

  • Written expression

  • Math (dyscalculia)

  • 80% of SLD cases = reading problems.

    • Dysphonic dyslexia: Most common type (phonological)

C. Associated Features
  • Average or above-average IQ

  • Common Comorbidity: ADHD

  • Prevalence: 5–15% of school-aged children

VIII. EPPP Quick Reference Summary

  • IDD: IQ < 70 + adaptive deficits + early onset

  • ASD: Social communication deficits + repetitive behaviors

  • ADHD: 6 symptoms/5 symptoms; before 12; 2+ settings

  • Tourette’s: Motor + vocal tics 1+ year

  • SLD: Academic difficulties 6+ months despite intervention

  • ASD Best Prognosis: IQ > 70, language by age 5

  • ADHD Most Common Comorbidity: Oppositional Defiant Disorder (ODD)

  • Tourette’s Most Common Comorbidity: ADHD

IX. Schizophrenia Spectrum & Other Psychotic Disorders Study Sheet

1. Core Psychotic Symptoms
  • Delusions: Fixed false beliefs not culturally shared (e.g., persecutory, grandiose, somatic, referential, erotomanic, nihilistic).

  • Hallucinations: Sensory experiences without external stimulus (most common: auditory, usually voices).

  • Disorganized Thinking/Speech: Derailment, tangentiality, incoherence (“word salad”).

  • Grossly Disorganized or Catatonic Behavior: Bizarre behavior, agitation, rigid postures, mutism, negativism.

  • Negative Symptoms: Affective flattening, alogia (poverty of speech), avolition (lack of motivation), anhedonia (loss of pleasure), asociality (social withdrawal).

2. Main Diagnoses & Duration Differences (EPPP GOLD)
  • Think: “1 day → 1 month → 6 months → 6+ months”

- Brief Psychotic Disorder
  • Duration: ≥ 1 day but < 1 month

  • At least 1+ psychotic symptom, and one must be:

    • Delusions

    • Hallucinations

    • Disorganized speech

  • Eventual full return to premorbid functioning.

  • Often linked to a stressor (with marked stressor subtype).

- Schizophreniform Disorder
  • Duration: ≥ 1 month but < 6 months

  • Same core symptom set as schizophrenia (2+ key symptoms).

  • If symptoms last 6+ months → diagnosis becomes schizophrenia.

- Schizophrenia
  • Duration: ≥ 6 months total disturbance, with:

    • At least 1 month of active-phase symptoms.

  • Active-phase Symptoms (2+ must be significant):

    • Delusions

    • Hallucinations

    • Disorganized speech

    • Grossly disorganized or catatonic behavior

    • Negative symptoms

  • Must cause marked impairment in functioning (work, relationships, self-care).

  • Not better explained by mood disorder or by a substance/medical condition.

- Schizoaffective Disorder
  • An uninterrupted period of illness with a major mood episode (depressive or manic) concurrent with active-phase schizophrenia symptoms.

  • Plus:

    • At least 2 weeks of delusions or hallucinations without mood symptoms at some point.

    • Mood episodes (depression or mania) are present for most of the total duration.

  • Subtypes:

    • Bipolar type (includes manic ± depressive episodes)

    • Depressive type (only major depressive episodes)

  • Key EPPP rule:

    • If psychotic symptoms only occur during mood episodes → likely mood disorder with psychotic features (NOT schizoaffective).

3. Course & Prognosis in Schizophrenia
  • Typical Onset:

    • Late teens to mid-20s in males

    • Late 20s to early 30s in females

  • Prodromal phase: Social withdrawal, odd behavior, functioning decline.

  • Course: Can be chronic with exacerbations & remissions.

  • Symptoms often lessen with age (especially positive symptoms).

- Better Prognosis Associated With:
  • Later age of onset

  • Female gender

  • Acute onset vs. insidious

  • Good premorbid functioning

  • Presence of mood symptoms

  • Few negative symptoms

  • Strong social support

- Worse Prognosis Associated With:
  • Early onset

  • Male gender

  • Gradual onset

  • Strong negative symptoms

  • Family history of schizophrenia

  • High expressed emotion in family

4. Etiology of Schizophrenia
  • Genetics: Highly heritable; polygenic.

    • Twin/Family Studies:

    • General population risk: ~1%

    • First-degree relatives: ~10%

    • MZ twins: up to ~40–50% concordance

    • DZ twins: ~10–15%

  • Risk Increases with Degree of Genetic Relatedness:

    • Concordance Rate

    • Parent: 6%

    • Biological sibling: 9%

    • Child of one parent with schizophrenia: 13%

    • Child of two parents with schizophrenia: 46%

    • Dizygotic (fraternal) twin: 17%

    • Monozygotic (identical) twin: 48%

  • Neurotransmitters (Dopamine + more):

    • Classic Dopamine Hypothesis:

    • Schizophrenia due to overactivity of dopamine in certain brain areas.

    • Positive Symptoms: Linked to ↑ dopamine in mesolimbic pathway.

    • Negative/Cognitive Symptoms: Linked to ↓ dopamine in mesocortical pathway.

    • Revised Dopamine Hypothesis:

      • Positive symptoms = dopamine TOO HIGH in subcortical/striatal regions.

      • Negative symptoms = dopamine TOO LOW in prefrontal cortex.

  • Environmental & Developmental Factors:

    • Obstetric complications (e.g., hypoxia)

    • Prenatal viral infections

    • Malnutrition

    • Early CNS insult

    • Cannabis use (especially high-potency in adolescence) ↑ risk in vulnerable individuals

    • Stress/trauma and high expressed emotion can trigger relapse in vulnerable individuals.

5. Treatment of Schizophrenia
  1. Antipsychotic Medications:

    • First-Generation (Typical) Antipsychotics:

      • Mechanism: Strong D2 receptor blockade.

      • Best for positive symptoms.

      • Side Effects:

      • Extrapyramidal symptoms (EPS):

        • Acute dystonia (muscle spasms)

        • Parkinsonism (rigidity, tremor, bradykinesia)

        • Akathisia (inner restlessness)

      • Tardive dyskinesia (TD):

        • Involuntary movements (face, tongue, limbs), often after long-term use

        • May be irreversible

      • Neuroleptic malignant syndrome (rare but life-threatening):

        • Muscle rigidity, high fever, autonomic instability, confusion.

    • Second-Generation (Atypical) Antipsychotics:

      • Examples: Clozapine, risperidone, olanzapine, quetiapine, ziprasidone, aripiprazole.

      • Mechanism: Dopamine + serotonin receptor effects.

      • Effective for positive symptoms, often some benefit for negative symptoms.

      • Lower EPS risk (overall) but more:

      • Metabolic side effects:

        • Weight gain

        • Hyperlipidemia

        • Insulin resistance / diabetes

    • Clozapine (Special Case):

      • Very effective for treatment-resistant schizophrenia.

      • Serious risk: Agranulocytosis (dangerous drop in WBCs) → requires regular blood monitoring.

      • Also risk of seizures, myocarditis, significant weight gain/sedation.

  2. Psychosocial Interventions:

    • Best outcomes = meds + psychosocial.

    • Psychoeducation: Patient & family understanding of illness.

    • Family interventions: Reduce expressed emotion → lower relapse rates.

    • Social skills training: Improve communication, functioning.

    • CBT for psychosis: Target delusional beliefs, coping with voices.

    • Supported employment: Helps maintain work roles, structure, and recovery.

6. Cultural, Gender, and Age Considerations
  • Similar Lifetime Prevalence Across Cultures: (~1%)

    • Content of delusions/hallucinations can be culturally shaped.

  • Men:

    • Earlier onset

    • More negative symptoms

    • Generally poorer prognosis

  • Women:

    • Later onset

    • More mood symptoms

    • Better premorbid functioning

    • Slightly better prognosis

7. Suicide Risk in Schizophrenia
  • High suicide risk; estimates often around 5–10% die by suicide.

  • Risk Factors:

    • Young, male, higher functioning / more insight

    • Depressive symptoms

    • Hopelessness

    • Recent hospital discharge

    • History of suicide attempts

  • Many attempts occur during early course or after acute episodes.

8. EPPP-Style Distinctions (Quick Reference)
  • Duration / Diagnosis:

    • 1 day–<1 month → Brief psychotic disorder

    • 1–<6 months → Schizophreniform disorder

    • ≥6 months → Schizophrenia

    • Psychosis + mood most of the time + 2+ weeks psychosis alone → Schizoaffective

    • 1+ month delusions only, relatively intact functioning → Delusional disorder

  • Family Patterns:

    • Higher risk with closer genetic relationship, history of schizophrenia in first-degree relatives;

    • MZ twin studies: much higher concordance than DZ.

  • Treatment:

    • First-line: Antipsychotics (SGAs often preferred)

    • Clozapine: For treatment-resistant or high suicide risk

    • ECT: Sometimes used for catatonia or severe psychosis when meds fail

    • Psychosocial: family work, CBTp, social skills, supported employment

9. Bipolar & Depressive Disorders Study Sheet
1. Core Mood Episodes
  • Manic Episode:

    • Mood: Abnormally elevated, expansive, or irritable

    • Energy: ↑ Activity/Energy

    • Duration: ≥ 1 week (or any duration if hospitalization is needed)

    • Symptoms: 3+ (4+ if mood only irritable), e.g.:

    • Grandiosity/inflated self-esteem

    • Decreased need for sleep

    • Pressured speech

    • Flight of ideas/racing thoughts

    • Distractibility

    • ↑ goal-directed activity or psychomotor agitation

    • Risky behaviors (spending, sex, etc.)

    • Severity:

    • Marked impairment in functioning OR

    • Hospitalization to prevent harm OR

    • Psychotic features

  • Hypomanic Episode:

    • Mood: Elevated, expansive, or irritable

    • Energy: ↑ Activity/Energy

    • Duration: ≥ 4 consecutive days

    • Symptoms: Same list as mania (3+ or 4+ if irritable only)

    • Severity:

    • Change in functioning noticeable to others

    • NO marked impairment

    • NO hospitalization

    • NO psychotic features

  • Major Depressive Episode (MDE):

    • Duration: ≥ 2 weeks

    • Symptoms: 5+, with at least one being:

    • Depressed mood

    • Loss of interest/pleasure (anhedonia)

    • Other Possible Symptoms:

    • Appetite/weight change

    • Sleep disturbance (insomnia or hypersomnia)

    • Psychomotor agitation or retardation

    • Fatigue or loss of energy

    • Feelings of worthlessness or excessive guilt

    • Poor concentration/indecisiveness

    • Recurrent thoughts of death or suicide

    • Must cause clinically significant distress or impairment.

2. Bipolar Disorders
  • Bipolar I Disorder:

    • Requires at least one manic episode.

    • May also have hypomanic and/or major depressive episodes, but they’re not required.

    • If mania has EVER occurred → diagnosis is Bipolar I (for life).

  • Bipolar II Disorder:

    • Requires:

    • ≥ 1 hypomanic episode

    • ≥ 1 major depressive episode

    • Never had a manic episode.

    • If psychosis shows up in a mood episode → it’s mania → Bipolar I, not II.

  • Cyclothymic Disorder:

    • Numerous periods of:

    • Hypomanic symptoms that do not meet full hypomanic criteria

    • Depressive symptoms that do not meet full MDE criteria

    • Duration:

    • Adults: ≥ 2 years

    • Kids/teens: ≥ 1 year

    • Symptoms present at least half the time, with no symptom-free period > 2 months.

3. Etiology of Bipolar Disorder (High-Yield Points)
  • Highly heritable:

    • Heritability ≈ 60–90%

    • Twin concordance (approx ranges):

    • Monozygotic: 40–80%

    • Dizygotic: 5–30%

    • Some evidence heritability is greater for Bipolar I than II.

  • Environmental Risk Factors:

    • Early parental loss

    • Childhood maltreatment (esp. emotional abuse)

    • Medical comorbidities (IBS, asthma, migraine)

    • Substance use (e.g., cannabis, cocaine)

    • Highly stressful life events

4. Differential Diagnosis: Bipolar vs ADHD
  • Shared Symptoms:

    • Distractibility, irritability, accelerated speech.

  • Mania in Youth (7–16):

    • Most specific symptoms: Elation, Grandiosity, Flight of ideas/racing thoughts, Decreased need for sleep, Hypersexuality/developmentally inappropriate sexual behavior.

  • Adults:

    • Mania: Mood: Euphoric, elevated, or irritable; Self-esteem: ↑ self-esteem/grandiosity; Distractibility: Due to thought acceleration; Sleep: ↓ need for sleep without fatigue; Sexuality: Often ↑ sexual activity.

    • Adult ADHD: Mood: Labile, often dysphoric; Self-esteem: Reduced self-esteem; Distractibility: Wandering thoughts, not accelerated; Sleep: Fatigue and discomfort after loss of sleep; Sexuality: Not necessarily ↑ activity, but ↑ risk for sexual disorders and risky sexual behavior.

5. Treatment of Bipolar Disorder
  • Psychosocial Interventions:

    • Often combined with meds.

    • Psychoeducation, Interpersonal and Social Rhythm Therapy, CBT, and Family-focused therapy (targets high expressed emotion to reduce relapse).

  • Pharmacotherapy:

    • “Classic” bipolar disorder (best for lithium):

    • Low likelihood of mixed states or rapid cycling.

    • Long periods of recovery between episodes.

    • Onset ~15–19 years → Lithium usually most effective.

    • “Atypical” bipolar disorder (best for anticonvulsants/SGAs):

    • Mixed mood states.

    • Rapid cycling.

    • Lack of full recovery between episodes.

    • Earlier onset (~10–15 years) → Anticonvulsants (e.g., carbamazepine, valproic acid).

    • Second-generation antipsychotics (Note: “classic vs atypical” here is not a DSM-5-TR formal specifier.)

6. Depressive Disorders
  • Major Depressive Disorder (MDD):

    • 5+ MDE symptoms for ≥ 2 weeks.

    • At least one is depressed mood or anhedonia.

  • Persistent Depressive Disorder (PDD/Dysthymia):

    • Depressed mood plus 2+ symptoms (e.g., low appetite or overeating, insomnia/hypersomnia, low energy, low self-esteem, poor concentration, hopelessness).

    • Duration:

    • Adults: ≥ 2 years.

    • Kids/teens: ≥ 1 year.

    • If criteria for MDD are ALSO met → diagnose both MDD and PDD and add a PDD course specifier:

    • With persistent major depressive episode

    • With intermittent major depressive episode, with current episode

    • With intermittent major depressive episode, without current episode.

7. Disruptive Mood Dysregulation Disorder (DMDD)
  • Duration: ≥ 12 months.

  • Criteria:

    • Severe, recurrent temper outbursts (verbal and/or behavioral):

    • Out of proportion to situation

    • Occur ≥ 3 times per week.

    • Between outbursts: Persistently irritable or angry mood, visible to others most of the day, nearly every day.

8. MDD Specifiers: Peripartum Onset & Seasonal Pattern
  • With Peripartum Onset:

    • Onset: During pregnancy or within 4 weeks postpartum.

    • “Baby Blues”:

    • Up to 80% of women experience mild symptoms (sadness, irritability, anxiety).

    • Smaller % meet full MDD criteria.

    • About half of those with MDD had symptom onset before delivery.

    • Evidence-based treatments:

    • CBT

    • Interpersonal therapy (IPT)

    • Antidepressants (esp. sertraline) – must weigh:

      • Potential risks to fetus/breastfeeding infant

      • Risks of untreated maternal depression.

    • Exercise can help, especially when combined with other interventions.

  • With Seasonal Pattern (Seasonal Affective Disorder – SAD):

    • Temporal Pattern: Usually winter onset.

    • Typical Symptoms:

    • Hypersomnia

    • Overeating

    • Weight gain

    • Carb craving

    • Biology:

    • Low serotonin

    • High melatonin.

9. Gender, Age, and Depression
  • In Childhood: Depression rates similar for boys and girls.

  • In Adolescence:

    • Rate increases sharply for females.

    • Male rate stays relatively stable.

    • Female:male ratio ≈ 1.5 to 3:1 and persists into adulthood.

  • Older Adults:

    • Less likely to emphasize affective symptoms.

    • More likely to report somatic complaints, cognitive changes, loss of interest in activities.

10. Etiology of Major Depressive Disorder
  • Genetic Factors:

    • Heritability ≈ 30–50%.

    • Twin Concordance (approx):

    • MZ: ~46%

    • DZ: ~20%.

    • Genetic influence often higher in females.

  • Personality Trait Neuroticism: Accounts for a large part of genetic risk.

  • Neurotransmitters & Biology:

    • Depression associated with low serotonin, norepinephrine, dopamine.

    • HPA Axis Abnormalities:

    • Chronic stress → hyperactive HPA axis → ↑ cortisol → Increased risk for depression, especially with early life stress.

    • Brain Abnormalities:

    • Prefrontal cortex, cingulate cortex, hippocampus, basal ganglia, amygdala, thalamus, etc.

    • Pattern:

      • Ventromedial PFC (vmPFC) = overactive in depression

      • Dorsolateral PFC (dlPFC) = underactive in depression

      • Remission linked to ↓ vmPFC activity and ↑ dlPFC activity (after therapy or meds).

11. Behavioral & Cognitive Theories of Depression
  • Lewinsohn – Social Reinforcement Theory:

    • Low rate of response-contingent reinforcement for social behaviors → due to lack of environmental reinforcement and/or poor social skills → leads to social isolation, low self-esteem, pessimism, and further ↓ reinforcement → depression cycle.

  • Seligman – Learned Helplessness/Hopelessness Theory:

    • Original Model: Repeated exposure to uncontrollable negative events → helplessness → depression.

    • Reformulated: Negative events interpreted with stable, internal, global attributions → hopelessness is the immediate, sufficient cause of depression stemming from negative events + negative attributional style.

  • Beck – Cognitive Theory:

    • Negative cognitive triad: Negative view of self, world, future + cognitive distortions and automatic negative thoughts.

12. Age & Cultural Factors in MDD
  • Younger Adults:

    • Risk linked to genetics, stressful life events, limited problem-solving/coping skills.

  • Older Adults:

    • Chronic medical illness & reduced physical functioning = major risk factors.

    • Social isolation plays a large role.

  • Cultural Differences:

    • Some Latino, Mediterranean, Middle Eastern, Asian, and other non-Western groups: More likely to report somatic symptoms (sleep, appetite, pain, palpitations).

    • Western/Euro-Canadian patients: More likely to emphasize psychological symptoms (sadness, hopelessness, loneliness).

13. Comorbidity of MDD
  • Common Comorbidities:

    • Substance use disorders (esp. alcohol) – most common

    • Anxiety disorders

    • Personality disorders

  • Sleep Abnormalities:

    • Prolonged sleep latency.

    • Reduced REM latency.

    • Reduced slow-wave sleep.

    • Increased REM density.

  • Medical Comorbidities:

    • Coronary heart disease, stroke, diabetes, Parkinson’s disease, etc.

    • Often bidirectional: Depression ↑ risk for myocardial infarction; Depression and anxiety are common after MI, with depression more frequent.

14. Treatment of Major Depressive Disorder
  • General Findings:

    • Psychotherapy alone vs medications alone → similar effectiveness.

    • Combined therapy + medications → best for response & remission.

  • For MDD + SUD:

    • Concurrent treatment recommended (behavioral/CBT + pharmacotherapy) addressing both at once.

APA Guideline – by Age
  • Children:

    • Insufficient evidence to recommend any specific treatment as clearly superior.

  • Adolescents:

    • CBT or IPT-A recommended.

    • Fluoxetine = first-line medication.

    • Not enough evidence to say therapy vs fluoxetine is better.

  • Adults:

    • Offer either:

    • Psychotherapy (CBT, MBCT, IPT, behavioral, psychodynamic, supportive)

    • Second-generation antidepressant (SSRI/SNRI)

    • No clear “winner” among psychotherapies or between medications vs therapy.

    • Combined CBT/IPT + antidepressant especially for chronic or treatment-resistant depression.

  • Older Adults:

    • Group CBT or IPT + second-generation antidepressant.

    • Limited support for self-guided bibliotherapy or life review therapy.

15. Other Treatments
  • St. John’s Wort:

    • Similar efficacy to SSRIs for mild–moderate depression.

    • Fewer side effects, lower dropout.

    • Not effective for severe depression.

    • Significant drug interactions (with SSRIs or other serotonin-increasing medications → risk of serotonin syndrome).

  • Ketamine/Esketamine:

    • Fast-acting for treatment-resistant depression and suicidal ideation.

    • Mechanism: ↑ glutamate.

    • Esketamine: Nasal spray used with an oral antidepressant.

  • Electroconvulsive Therapy (ECT):

    • Very effective for severe or treatment-resistant depression.

    • Especially when rapid response is needed (e.g., high suicide risk).

    • Response/Remission Rates:

    • Response ≈ 80%.

    • Remission ≈ 70%.

    • Faster remission than meds or therapy:

    • ECT: 1–3 weeks.

    • IPT/CBT: 6–10 weeks.

    • Antidepressants: 4–12 weeks.

    • ECT and Memory:

    • Causes anterograde and retrograde amnesia.

    • Anterograde amnesia: Difficulty forming new memories after ECT; usually resolved within weeks.

    • Retrograde amnesia: Loss of memory from before ECT; more severe with bilateral electrode placement; some recent memories may not fully return.

  • Repetitive Transcranial Magnetic Stimulation (rTMS):

    • Noninvasive stimulation of left dorsolateral prefrontal cortex.

    • Used for treatment-resistant depression.

    • Advantages: No sedation, no memory loss.

    • Disadvantage: Lower response and remission rates than ECT.

  • Telepsychology vs. In-Person Therapy:

    • Outcomes are similar: Symptom reduction, Quality of life, Client satisfaction, Therapeutic alliance.

  • Physical Activity/Exercise:

    • Physical activity reduces depressive symptoms even at lower-than-recommended levels.

    • Evidence suggests: Exercise, therapy, and antidepressants can have comparable effects in mild–moderate depression; Adding exercise → improved outcomes.

16. Suicide in the United States – Key Patterns
  • Gender & Age:

    • Men: Suicide rate ≈ 4x women

    • Highest male rate: 75+ years

    • Highest female rate: 45–64 years

  • Race/Ethnicity:

    • Highest rates: Non-Hispanic American Indian/Alaska Native individuals.

  • Veterans:

    • Higher suicide rate than non-veterans; e.g., rates roughly double the general adult rate.

  • Incarceration:

    • Higher rates among currently incarcerated and previously incarcerated.

  • Transgender vs. Cisgender Individuals:

    • Much higher rates of suicidal ideation and suicide attempts among transgender adults and youth.

XVII. PsychoPathology – Anxiety Disorders & OCD Study Notes

OVERVIEW – Anxiety Disorders
  • Common Features: Excessive fear + anxiety + behavioral avoidance.

  • Risk Factors:

    • Stressful life events

    • Behavioral inhibition temperament

    • Having an anxious parent (x2 risk)

    • Heritability: 30–50%.

    • MZ twins > DZ twins.

1. Separation Anxiety Disorder
  • Key Features:

    • Excessive, developmentally inappropriate fear of separation.

    • Need 3+ symptoms (crying at separation, physical complaints, avoidance of leaving home, etc.)

    • Duration: 4 weeks (kids) / 6 months (adults)

  • School Refusal Clue: Wants to stay home with caregiver, not avoid school itself.

  • Treatment:

    • CBT (psychoeducation, exposure, relaxation, restructuring)

    • Add parent training = improves outcomes.

    • For school refusal → priority = get child back into school quickly.

2. Specific Phobia
  • Definition: Fear of a specific object/situation + avoidance or enduring with intense distress; persistent 6+ months.

  • Types:

    • Animal

    • Natural environment

    • Blood-injection-injury

    • Situational

    • Other

  • Etiology:

    • 30–50% heritability.

    • Amygdala hyperactivity (fear generation).

    • vPFC/vACC underactivity (poor fear regulation).

  • Mowrer’s Two-Factor Theory:

    • Step 1: Classical Conditioning → creates fear.

    • Step 2: Operant Conditioning → maintains fear.

3. Social Anxiety Disorder
  • Key Symptoms:

    • Fear of scrutiny.

    • Fear of showing symptoms → negative evaluation.

    • Avoidance OR endure with intense fear.

  • Duration: Persistent = 6+ months.

  • Treatment:

    • CBT (cognitive restructuring + exposure)

    • SSRIs/SNRIs

    • Internet-delivered CBT = as effective as face-to-face.

    • School-based CBT effective for youth.

4. Panic Disorder
  • Diagnosis:

    • recurrent unexpected panic attacks.

    • At least one attack followed by 1+ month of:

    • Worry about additional attacks.

    • Maladaptive behavior change.

  • Rule Out: Hyperthyroidism, cardiac issues, etc.

  • Symptoms (need 4+):

    • Palpitations

    • Sweating

    • Trembling

    • Derealization

    • Fear of dying

    • Nausea

    • Chest pain

    • Dizziness

  • Treatment:

    • Panic Control Treatment (PCT) – Interoceptive exposure (spin, run, breathe through straw) – relaxation + cognitive skills.

    • Antidepressants (imipramine) or benzos = help but high relapse from use alone.

5. Agoraphobia
  • Fear in 2+ of 5 Situations:

    • Public transport

    • Open spaces

    • Enclosed spaces

    • Crowds/lines

    • Being outside home alone.

  • Treatment:

    • In vivo exposure (graded or intense).

    • Evidence combining in vivo exposure with applied relaxation, breathing retraining, or cognitive techniques does not significantly improve outcomes.

    • Key mechanism = learning to tolerate high levels of fear and anxiety.

6. Generalized Anxiety Disorder (GAD)
  • Key Features:

    • Excessive, uncontrollable worry about multiple areas.

    • Occurs most days for 6+ months.

  • Requires 3+ Symptoms (1+ for kids):

    • Restlessness

    • Fatigue

    • Difficulty concentrating

    • Irritability

    • Muscle tension

    • Sleep problems.

  • Most Common Comorbid Disorder: Major Depression.

Theories of Worry (Know these!)
  1. Cognitive Avoidance Theory (Borkovec):

    • Worry is verbal to avoid strong emotions; verbalizes instead of picturing scary things; emotional avoidance strategy.

  2. Contrast Avoidance Model (Newman & Llera):

    • People with GAD remain in a steady low-grade negative mood to avoid sudden drops to negative; emotional bracing.

  3. Intolerance of Uncertainty Model (Dugas):

    • Allergic to uncertainty + doubt in coping + belief that worry is necessary + avoid mental imagery.

Neurobiology GAD:
  • Abnormalities in:

    • Amygdala (hyperreactive)

    • Prefrontal cortex + ACC → reduced connectivity → weak top-down regulation.

  • Risk Factors: Anxiety family history, Trauma, chronic stress, Temperament: behavioral inhibition, harm avoidance, neuroticism.

  • Treatment:

    • CBT = best (alone or with meds) better than meds alone.

    • SSRIs & SNRIs = first line.

    • Buspirone (Buspar) used as adjunct (when antidepressant is only partially effective).


Obsessive-Compulsive and Related Disorders
1. Obsessive-Compulsive Disorder (OCD)
  • Obsessions::

    • Intrusive, unwanted thoughts → cause distress.

  • Compulsions:

    • Repetitive behaviors/mental rituals → reduce anxiety or prevent harm.

  • Time Requirement: > 1 hour/day or significant impairment.

  • Insight Specifier: Good/fair, poor, absent/delusional beliefs.

  • Etiology:

    • Heritability:

    • Adults 27–57%

    • Children 45–65%

    • CSTC pathway hyperactivity: Orbitofrontal → basal ganglia → thalamus → back to cortex

    • Amygdala involvement (fear/anxiety).

  • Treatment:

    • ERP (Exposure + Ritual Prevention) = gold standard.

    • SSRIs.

    • Combined ERP + SSRI = best for:

    • Severe symptoms

    • ERP/SSRI nonresponse

    • Comorbidities treated with antidepressants.

    • Motivational interviewing pretreatment boosts outcomes.

    • ERP delivered in-person or telehealth = equally effective for children & teens.

2. Body Dysmorphic Disorder (BDD)
  • Key Features:

    • Preoccupation with imagined/minor defect in appearance.

    • Repetitive behaviors (mirror checking, grooming, skin picking).

    • Distress or impairment.

    • May include ideas/delusions of reference.

    • Often seeks cosmetic procedures.

Summary for Exam Recall
  • Separation Anxiety: Child clings, physical complaints → CBT + parent training.

  • Specific Phobia: Exposure (in vivo); blood-injection → applied tension.

  • Social Anxiety: CBT + SSRIs/SNRIs; internet CBT works.

  • Panic Disorder: Panic Control Treatment (interoceptive exposure).

  • Agoraphobia: Exposure only, nothing fancy.

  • GAD: Worry theories, CBT, SSRIs/SNRIs, intolerance of uncertainty.

  • OCD: ERP, SSRIs, combined for severe cases.

  • BDD: Preoccupation + repetitive behaviors.

Next Steps
  • Continue with trauma/disassociation/somatic disorders.